Medicines labeled for the same conditions
Alternatives to bosentan
6 other medicines are given the same way (oral) and in the same FDA class as bosentan or labeled mainly for the same use (pulmonary arterial hypertension); 3 are in its class, endothelin receptor antagonists: ambrisentan, macitentan and macitentan and tadalafil; the others include 1 prostacyclin receptor agonist, 1 prostacycline vasodilator and 1 soluble guanylate cyclase stimulator (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $8.02 per ambrisentan 10 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as bosentan?
Pulmonary arterial hypertension lists all 11 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Bosentanendothelin receptor antagonist | this medicine | 5 labelers | n/a | Yes | No current entry |
| Ambrisentanendothelin receptor antagonist · same class | Pulmonary arterial hypertension | 12 labelers | $8.02 per tablet 10 mg tablet | Yes | No current entry |
| Macitentanendothelin receptor antagonist · same class | Pulmonary arterial hypertension | 13 labelers | n/a | Yes | No current entry |
| Macitentan and tadalafilphosphodiesterase 5 inhibitor · same class | Pulmonary arterial hypertension | none listed | n/a | Yes | No current entry |
| Selexipagprostacyclin receptor agonist | Pulmonary arterial hypertension | 2 labelers | n/a | No | No current entry |
| Treprostinilprostacycline vasodilator | Pulmonary arterial hypertension | none listed | n/a | No | No current entry |
| Riociguatsoluble guanylate cyclase stimulator | Pulmonary arterial hypertension | 1 labeler | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Bosentan: the full record
- label, generics, price, shortages, recalls
- Bosentan vs ambrisentan
- two records side by side